Phreesia Management

Management criteria checks 2/4

Phreesia's CEO is Chaim Indig, appointed in Jan 2005, has a tenure of 19.42 years. total yearly compensation is $8.27M, comprised of 6% salary and 94% bonuses, including company stock and options. directly owns 2.28% of the company’s shares, worth $26.70M. The average tenure of the management team and the board of directors is 3.6 years and 16.7 years respectively.

Key information

Chaim Indig

Chief executive officer

US$8.3m

Total compensation

CEO salary percentage	6.0%
CEO tenure	19.4yrs
CEO ownership	2.3%
Management average tenure	3.6yrs
Board average tenure	16.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chaim Indig's remuneration changed compared to Phreesia's earnings?
Date	Total Compensation	Salary	Company Earnings
Apr 30 2024	n/a	n/a	-US$119m
Jan 31 2024	US$8m	US$495k	-US$137m
Oct 31 2023	n/a	n/a	-US$144m
Jul 31 2023	n/a	n/a	-US$152m
Apr 30 2023	n/a	n/a	-US$162m
Jan 31 2023	US$8m	US$515k	-US$176m
Oct 31 2022	n/a	n/a	-US$185m
Jul 31 2022	n/a	n/a	-US$181m
Apr 30 2022	n/a	n/a	-US$158m
Jan 31 2022	US$9m	US$515k	-US$118m
Oct 31 2021	n/a	n/a	-US$80m
Jul 31 2021	n/a	n/a	-US$50m
Apr 30 2021	n/a	n/a	-US$32m
Jan 31 2021	US$6m	US$419k	-US$27m
Oct 31 2020	n/a	n/a	-US$23m
Jul 31 2020	n/a	n/a	-US$19m
Apr 30 2020	n/a	n/a	-US$83m
Jan 31 2020	US$10m	US$346k	-US$91m
Oct 31 2019	n/a	n/a	-US$102m
Jul 31 2019	n/a	n/a	-US$113m
Apr 30 2019	n/a	n/a	-US$54m
Jan 31 2019	US$510k	US$300k	-US$45m

Compensation vs Market: Chaim's total compensation ($USD8.27M) is above average for companies of similar size in the UK market ($USD1.37M).

Compensation vs Earnings: Chaim's compensation has increased whilst the company is unprofitable.

CEO

Chaim Indig (44 yo)

19.4yrs

Tenure

US$8,273,307

Compensation

Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chaim Indig	Co-Founder	19.4yrs	US$8.27m	2.28% $ 26.7m
Evan Roberts	Co-Founder & COO	19.4yrs	US$4.50m	1.21% $ 14.2m
Balaji Gandhi	Chief Financial Officer	1.3yrs	US$5.91m	0.047% $ 555.1k
Allison Hoffman	General Counsel & Secretary	3.8yrs	US$3.04m	0.056% $ 650.5k
David Linetsky	Senior Vice President of Life Sciences	5.3yrs	US$4.47m	0.21% $ 2.4m
Janet Gunzburg	VP, Principal Accounting Officer & Controller	1.2yrs	no data	0.061% $ 713.3k
Jack Callahan	Chief Technology Officer	less than a year	no data	no data
Maureen McKinney	Vice President of Corporate Communications	3.4yrs	no data	no data
Amy VanDuyn	Senior Vice President of Human Resources	14.2yrs	no data	0.21% $ 2.4m
Hilary Hatch	Chief Clinical Officer	3.2yrs	no data	no data
Melissa Mitchell	Chief Privacy Officer	less than a year	no data	no data
Charles H. Kallenbach	Secretary	7.7yrs	US$421.01k	no data

3.6yrs

Average Tenure

49.5yo

Average Age

Experienced Management: 0A23's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Chaim Indig	Co-Founder	19.4yrs	US$8.27m	2.28% $ 26.7m
Eve Kurtin	Board Observer	no data	no data	no data
Edward Cahill	Independent Director	16.7yrs	US$232.46k	0.062% $ 729.3k
Michael Weintraub	Independent Chairman	19.4yrs	US$384.98k	0.29% $ 3.4m
Richard Jackson	Member of Medical Advisory Board	no data	no data	no data
Gillian Munson	Independent Director	5.1yrs	US$257.46k	0.018% $ 208.6k
Elsa-Grace Giardina	Member of Medical Advisory Board	no data	no data	no data
Mark Blais	Member of Medical Advisory Board	no data	no data	no data
Michael Brodman	Member of Medical Advisory Board	no data	no data	no data
Lee Schwamm	Member of Medical Advisory Board	no data	no data	no data
Susan MacDonald	Member of Medical Advisory Board	no data	no data	no data
Mark Smith	Independent Director	5.7yrs	US$244.98k	0.011% $ 124.7k

16.7yrs

Average Tenure

62yo

Average Age

Experienced Board: 0A23's board of directors are seasoned and experienced ( 16.7 years average tenure).

Phreesia Management

Management criteria checks 2/4

Key information

Recent management updates

Phreesia, Inc., Annual General Meeting, Jun 26, 2024

Chief Financial Officer recently sold US$176k worth of stock

Phreesia Appoints Jack Callahan as Chief Technology Officer

Co-Founder recently sold US$1.6m worth of stock

Co-Founder recently sold US$133k worth of stock

Insufficient new directors

Recent updates

New major risk - Financial position

Phreesia, Inc. Updates Earnings Guidance for the Year 2025

Phreesia, Inc. Updates Earnings Guidance for the Year 2025

Phreesia, Inc., Annual General Meeting, Jun 26, 2024

Phreesia, Inc. to Report Q1, 2025 Results on May 30, 2024

Chief Financial Officer recently sold US$176k worth of stock

Phreesia Appoints Jack Callahan as Chief Technology Officer

Full year 2024 earnings released: US$2.51 loss per share (vs US$3.36 loss in FY 2023)

Phreesia, Inc. to Report Q4, 2024 Results on Mar 14, 2024

Co-Founder recently sold US$1.6m worth of stock

Third quarter 2024 earnings released: US$0.58 loss per share (vs US$0.76 loss in 3Q 2023)

Phreesia, Inc. Provides Earnings Guidance for the Fiscal Year 2024 and Fiscal Year 2025

Phreesia, Inc. to Report Q3, 2024 Results on Dec 05, 2023

Co-Founder recently sold US$133k worth of stock

Phreesia, Inc. Reaffirms Earnings Guidance for the Full Fiscal Year Ending January 31, 2024 and Fiscal Year 2025

Phreesia, Inc. Reaffirms Earnings Guidance for the Full Fiscal Year Ending January 31, 2024 and Fiscal Year 2025

Second quarter 2024 earnings released: US$0.68 loss per share (vs US$0.89 loss in 2Q 2023)

Insufficient new directors

New major risk - Revenue and earnings growth

Insufficient new directors

Phreesia, Inc. to Report Q2, 2024 Results on Sep 06, 2023

Phreesia, Inc. Appoints Lisa Egbuonu-Davis to Board of Directors

Insufficient new directors

Phreesia, Inc.(NYSE:PHR) dropped from Russell Small Cap Comp Value Index

First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.99 loss in 1Q 2023)

Insufficient new directors

Phreesia, Inc., Annual General Meeting, Jun 28, 2023

Insufficient new directors

Full year 2023 earnings released: US$3.36 loss per share (vs US$2.37 loss in FY 2022)

Insufficient new directors

Phreesia, Inc. to Report Q4, 2023 Results on Mar 22, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$0.71 loss in 3Q 2022)

Phreesia, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Insufficient new directors

Phreesia, Inc. to Report Q3, 2023 Results on Dec 08, 2022

Second quarter 2023 earnings released

Insufficient new directors

Phreesia, Inc. Updates Revenue Outlook for Fiscal Year 2023

Insufficient new directors

Phreesia, Inc. to Report Q2, 2023 Results on Sep 07, 2022

Insufficient new directors

Phreesia, Inc. Provides Earning Guidance for Fiscal 2023 and 2025

Phreesia, Inc., Annual General Meeting, Jun 30, 2022

Phreesia, Inc. to Report Q1, 2023 Results on Jun 02, 2022

Full year 2022 earnings released: US$2.37 loss per share (vs US$0.69 loss in FY 2021)

Phreesia, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Phreesia, Inc. to Report Q4, 2022 Results on Mar 30, 2022

Phreesia, Inc. (NYSE:PHR) acquired Insignia Health, LLC from University of Oregon and others.

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Phreesia, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2022 earnings released: US$0.48 loss per share (vs US$0.17 loss in 2Q 2021)

Phreesia, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Independent Director recently sold US$300k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.16 loss in 1Q 2021)

Phreesia, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: US$0.69 loss per share (vs US$4.50 loss in FY 2020)

Phreesia, Inc. Provides Earnings Guidance for the Year Ending January 31, 2022

Phreesia, Inc. to Report Q4, 2021 Results on Mar 30, 2021

Insider recently sold US$330k worth of stock

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age